title: Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling.
abstract: Effective integration of in vitro tests and absorption modeling can greatly improve our capability in understanding, comparing, and predicting in vivo performances of clinical drug products. In this case, we used a proprietary drug candidate galunisertib to describe the procedures of designing key in vitro tests, analyzing relevant experimental and trial data, and integrating them into physiologically based absorption models to evaluate the performances of its clinical products. By simulating the preclinical study result, we estimated high in vivo permeability for the drug. Given the high sensitivity of its solubility to pH, supersaturation may play an important role in the absorption of galunisertib. Using the dynamic dissolution test, i.e., artificial stomach-duodenum (ASD) model and simulation, we concluded galunisertib in solution or tablet products could maintain supersaturation during the transit in the gastrointestinal tract (GIT). A physiologically based absorption model was established by incorporating these key inputs in the simulation of Trial 1 results of galunisertib solution. To predict the performance of three tablet products, we developed z-factor dissolution models from the multi-pH USP dissolution results and integrate them into the absorption model. The resultant biopharmaceutical models provided good prediction of the extent of absorption of all three products, but underestimated the rate of absorption of one tablet product. Leveraging the ASD result and optimization with the dissolution model, we identified the limitation of the model due to complexity of estimating the dissolution parameter z and its in vitro-in vivo correlation.
authors.affiliation: Lilly Research Laboratory, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, 46285, USA.
authors.forename: Xuan
authors.initials: X
authors.lastname: Ding
authors.affiliation: Lilly Research Laboratory, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, 46285, USA.
authors.forename: Ivelina
authors.initials: I
authors.lastname: Gueorguieva
authors.affiliation: Lilly Research Laboratory, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, 46285, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Wesley
authors.affiliation: Lilly Research Laboratory, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, 46285, USA.
authors.forename: Lee J
authors.initials: LJ
authors.lastname: Burns
authors.affiliation: Lilly Research Laboratory, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, 46285, USA. cacoutant@lilly.com.
authors.forename: Carrie A
authors.initials: CA
authors.lastname: Coutant
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000818:Animals; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D010539:Permeability; D011720:Pyrazoles / Q000008:administration & dosage* / Q000097:blood*; D011804:Quinolines / Q000008:administration & dosage* / Q000097:blood*; D051381:Rats; D011916:Rats, Inbred F344; D012995:Solubility
chemical_list: D011720:Pyrazoles; D011804:Quinolines; C557799:LY-2157299
keywords: absorption; dissolution; physiologically based model; z-factor